Yifan Zhai

机构：Ascepion Pharmaceuticals (China), Ascendis Pharma (Denmark) · ORCID：0000-0003-1672-2262

发表论文 246 篇 · 总被引 3836 次 · h-index 27

代表论文

• Olverembatinib in chronic myeloid leukemia—Review of historical development, current status, and future research (2025 · Cancer · 被引 8)
• A phase 2 study of novel MDM2 inhibitor alrizomadlin (APG-115) with or without toripalimab in patients (pts) with advanced adenoid cystic carcinoma (ACC) or other solid tumors. (2025 · Journal of Clinical Oncology · 被引 5)
• Bivalent SMAC mimetic APG-1387 reduces HIV reservoirs and limits viral rebound in humanized mice (2024 · iScience · 被引 4)
• Results of POLARIS-1, a global Phase 3 study (Part A): Olverembatinib combined with low-intensity chemotherapy in patients with newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) (2025 · Blood · 被引 2)
• Safety, pharmacokinetic, pharmacodynamic, and efficacy properties of orally administered APG-2449 in patients with advanced ALK and ROS1 non-small-cell lung cancer: a multicentre, open-label, single-arm phase 1 trial (2025 · EClinicalMedicine · 被引 2)
• Targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition to delay emergence of acquired resistance of lung cancer to osimertinib (2025 · Cancer Letters · 被引 2)